
Friday, October 04, 2024 2:13:54 PM
Recent IOBT News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2025 09:47:03 PM
- IO Biotech Reports 2024 Business Highlights • GlobeNewswire Inc. • 03/04/2025 09:17:04 PM
- IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference • GlobeNewswire Inc. • 02/23/2025 05:07:39 PM
- IO Biotech to Present at the 45th Annual Cowen Health Care Conference • GlobeNewswire Inc. • 02/20/2025 01:05:00 PM
- IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate • GlobeNewswire Inc. • 02/04/2025 01:05:00 PM
- IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer • GlobeNewswire Inc. • 01/09/2025 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2024 09:16:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2024 01:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2024 11:56:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2024 11:53:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 01:10:30 PM
- IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank • GlobeNewswire Inc. • 12/20/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2024 11:06:59 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 12:11:53 PM
- IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 11/12/2024 12:05:00 PM
- IO Biotech Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/11/2024 09:05:00 PM
- IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study • GlobeNewswire Inc. • 11/07/2024 03:00:00 PM
- IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting • GlobeNewswire Inc. • 10/04/2024 01:00:00 PM
- IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer • GlobeNewswire Inc. • 09/14/2024 06:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:10:54 PM
- IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma • GlobeNewswire Inc. • 08/30/2024 08:05:00 PM
- IO Biotech Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/26/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:06:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:05:59 AM
FEATURED Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 • Mar 10, 2025 9:05 AM
North Bay Resources Announces Assays up to 5.69% Copper, 1 Opt. Silver, and 0.22% Vanadium at Copper Island Project, British Columbia • NBRI • Mar 10, 2025 9:00 AM
Avant Technologies and JV Partner, Ainnova, Strategically Align with Apollo Hospitals to Advance AI in Healthcare • AVAI • Mar 10, 2025 8:00 AM
Veri Medtech (VRHI) Network Grows To 400 Physicians • VRHI • Mar 10, 2025 7:32 AM
One World Products' Isiah Thomas Issues Investor Update • OWPC • Mar 6, 2025 9:19 AM
Authentic Holdings To Reduce Debt by over $2 Million While Achieving Substantial Revenue Growth • AHRO • Mar 6, 2025 8:00 AM